Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
Key facts
- Who runs it
- University of Sao Paulo General Hospital
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 200 people, planned
- Started
- 2 Dec 2025
- Expected to end
- 30 Jul 2028
- Type of study
- Interventional
- Treatments tested
- Recombinant Zoster Vaccine (RZV)
- Record updated
- 11 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adults aged 18 years or older
- Diagnosis of an autoimmune rheumatic disease (such as rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, psoriatic arthritis, systemic sclerosis, Sjögren syndrome, idiopathic inflammatory myopathies, or primary systemic vasculitis) according to validated classification criteria
- Clinical stability at the time of enrollment, defined as no change in disease-modifying therapy or corticosteroid dose in the preceding four weeks and no evidence of infection or disease flare
- Current use of hydroxychloroquine or sulfasalazine in monotherapy for at least three months prior to inclusion
- Can be under prednisone use of 5mg/week
- Ability and willingness to comply with study procedures and follow-up visits
- Provision of written informed consent
Who cannot take part
- Previous vaccination with recombinant zoster vaccine (RZV)
- History of herpes zoster or varicella infection within 12 months before enrollment
- Concomitant use of systemic immunosuppressive therapy including but not limited to methotrexate, mycophenolate mofetil, azathioprine, cyclophosphamide, biologics, or JAK inhibitors
- Acute febrile illness or active infection at the time of vaccination
- Known hypersensitivity to any component of the recombinant zoster vaccine
- History of Guillain-Barré syndrome
- Any condition that, in the investigators' judgment, could interfere with study participation or interpretation of results
- Use of glucocorticoids >5mg/week
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This interventional phase IV clinical trial will evaluate the efficacy, immunogenicity and safety of the adjuvanted recombinant herpes zoster vaccine (RZV) in adults with autoimmune rheumatic diseases (ARDs) receiving immunomodulatory monotherapy. Humoral immune response will be quantified by anti-glycoprotein E (anti-gE) antibody titers. Patients will receive two doses of RZV. Outcomes include seroconversion and geometric mean titers six weeks after completion of the vaccination schedule, persistence of antibody titers at one year, and incidence of confirmed herpes zoster during follow-up.
The group in the trial
- Immunomodulator MonotherapyTreatment being tested
Participants with autoimmune rheumatic diseases who are clinically stable and receiving monotherapy with hydroxychloroquine or sulfasalazine will receive two doses of the recombinant zoster vaccine (RZV, Shingrix) administered intramuscularly on Day 0 and Day 42. Immunogenicity will be evaluated through anti-glycoprotein E antibody titers at baseline, six weeks, and one year after vaccination. Safety, disease activity, and incidence of herpes zoster will be monitored throughout follow-up.
Treatment: Recombinant Zoster Vaccine (RZV)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy, Immunogenicity, and Safety of the Recombinant Herpes Zoster Vaccine (RZV) in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators
- Record updated
- 11 March 2026